



## **GE Healthcare & Zai Lab Enter a Strategic Partnership to Co-Develop a World Class Biotherapeutics Clinical Production Center**

March 31, 2017

**March, 30<sup>th</sup>, 2017, Shanghai, China** —GE Healthcare and Zai Lab Limited signed a strategic partnership agreement and made a joint announcement to build Zai Lab – GE Biotherapeutics Development & Manufacturing/Processing Demonstration Site in Suzhou Biobay, Jiangsu Province. This facility will be equipped with the GE Healthcare FlexFactory™ platform featuring current good manufacturing practices (cGMP) that will meet both CFDA and the US FDA-compliance requirements. With this agreement, Zai Lab and GE Healthcare take on the mission of promoting biologics development in China and worldwide. Both companies will leverage this platform with world-class experts to provide intensive and systematic training for biopharmaceutical, academic, and institutional organizations and develop technical experts and industrial leaders in manufacturing/processing technology and applications in China.

The FlexFactory™ is configured to include GE's single-use systems and automation protocols. Compared with traditional manufacturing processes, FlexFactory™ platform is more cost-effective and flexible. This platform will quickly enable Zai Lab to establish their biologics clinical supply capability and expedite the drug discovery process and improve R&D productivity.

General Manager of GE Healthcare Life Sciences China, Mr. Qing Li, commented "As the partner of China bio-manufacturing industry, GE Healthcare is committed to provide the most advanced technology, wide variety of products, comprehensive service and abundant customized solutions. We are very excited to form this strategic partnership with Zai Lab and will use our first-class services to improve their manufacturing capacity and capability, speed up their effort in bringing high-quality and affordable biomedicines to Chinese patients. "

Chairman and CEO of Zai Lab, Dr. Samantha Du said: "Since August 2015, CFDA has announced a series of regulatory reform measures to encourage innovative drug discovery and development in China.

Local governments also responded quickly with supportive policies to further promote the biopharmaceutical industry. Zai Lab has made it our mission to develop innovative therapeutics in China for both local and global patients. We also established a world-class biologics drug discovery platform in Shanghai that will produce a series of novel drug candidates. We are delighted to work with GE Healthcare to build this highly advanced and flexible Biotherapeutics Clinical Production Center in Suzhou Biobay to support our clinical production demands. With this added capacity, Zai Lab can rapidly expand our research pipelines. I truly believe that innovative biotherapeutics discovered and developed by Zai Lab will be brought to market and benefit patients in the near future".

### **About GE Healthcare**

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.

The broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, GE partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

The "Healthymagination" vision of GE Healthcare for the future invites the world to join the journey to continuously develop innovations focused on reducing costs, increasing access and improving quality around the world.

Headquartered in Chicago, IL, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries.

### **About GE healthcare life sciences**

The Life Sciences business of GE Healthcare exists to enable and accelerate molecular and precision medicine. We do this by helping our customers discover, make and use new medicines.

Healthcare needs more precise diagnoses and treatments to improve patient outcomes, address the globally rising incidence of lifestyle and chronic diseases, and help reduce the \$350 billion wasted each year on poorly-targeted medicines.

GE healthcare life sciences (GELS) empower researchers with the innovative tools and analytics to research and develop tomorrow's therapeutics; drive productivity for the biopharmaceutical industry and help create manufacturing capacity in under-served markets. We enable increasingly accurate diagnoses by providing advanced in vivo imaging agents & in vitro diagnostics; help create the future of regenerative medicine and cell therapy with customers by providing novel tools, technologies and methods; work on the things that matter to become trusted partners with our customers, combining deep expertise, integrity, and heritage in diagnostics and biotechnology with an extensive global network and strength in infrastructure and services.

GELS is a \$4.0 billion business of GE Healthcare serving researchers, pharmaceutical companies, and clinicians.

**About Zai Lab Ltd.**

Zai Lab is a Shanghai-based biopharmaceutical company. Its globally-experienced drug development team is passionate about bringing transformative medicines to China and discovering and developing novel therapeutics for patients worldwide. The vision at Zai Lab is to create a premier drug discovery, development, manufacturing and commercialization organization built on a foundation of world-class expertise and insights into the existing and expanding needs of Chinese patients. Zai Lab has a team of leaders who have a collective track record in all aspects of our business, including pioneering success in the regulatory process in China. They have established a pipeline of best-in-class biopharmaceuticals at different stages of development by securing partnerships with leading multinational pharmaceutical and highly innovative biotechnology companies. Their pipeline will grow through additional collaborations and from internal discovery and development efforts.